Study of the effectiveness of shampoo application (combination of 3% salicylic acid, piroctone olamine and panthenol) as an external therapy of scalp psoriasis

Close metadata

BACKGROUND

Lesions of the scalp are common problem in psoriasis. Desquamation, plaques, crusts, erythema affect the appearance of patients, cause psychological discomfort among them, reduce the activity and life quality, sometimes lead to anxiety and depression. There are many drugs for the treatment of psoriasis, but the proper care, consisting in effective and timely cleansing of the scalp, is extremely important.

OBJECTIVE

To study the impact of including shampoo containing 3% salicylic acid, piroctone olamine and panthenol in complex external therapy of scalp psoriasis on clinical effectiveness and patient satisfaction with treatment.

MATERIAL AND METHODS

Open comparative study in parallel groups was carried out. Desquamation, itching, erythema, infiltration and life quality of patients, the presence of anxiety and depression with subsequent comparison of obtained results were assessed before and on the 7th, 14th and 21st days of treatment.

RESULTS

The study involved 60 patients with psoriasis and scalp lesions (spray active components of which were betamethasone dipropionate and 2% salicylic acid was used in the 1st group, and similar spray plus shampoo containing 3% salicylic acid, piroctone olamine and panthenol were used in the 2nd group). The severity of main symptoms in the groups was similar before treatment (p>0.05), and there was a more pronounced regression (p<0.05) in the 2nd group after treatment. The average score by the DLQI before treatment in the 1st and 2nd groups was 18.43 and 16.46 (p>0.05), respectively, and it was significantly lower (2.83 scores against 7.1 ones, p=0.004) on the 21st day in the 2nd group, as well as the average on the depression scale (2.4 scores against 6.83 ones; p=0.032).

CONCLUSION

Application of shampoo containing 3% salicylic acid, piroctone olamine and panthenol in patients with scalp psoriasis in combination with spray, active components of which were betamethasone dipropionate and 2% salicylic acid, allows not only to achieve the expected therapeutic effect from a combination of topical corticosteroid and keratolytic, but also to improve the life quality by improving appearance, reducing psychological discomfort and decreasing anxiety.

Keywords:

psoriasis

scalp

salicylic acid

betamethasone dipropionate

piroctone olamine

effectiveness

life quality

Authors:

Dvoryankova E.V.

Center for Theoretical Problems of Physicochemical Pharmacology RAS;
Bashkir State Medical University

ORCID: 0000-0002-2458-419X

Khismatullina Z.R.

Bashkir State Medical University, Russia

ORCID: 0000-0001-8674-2803

Sultanova E.A.

Bashkir State Medical University

ORCID: 0000-0002-3708-1145

Koreshkova K.M.

Bashkir State Medical University, Russia

ORCID: 0000-0001-6039-8311

Received:

16.10.2023

Accepted:

16.11.2023

List of references:

Fotiadou C, Lazaridou E, Sotiriou E, Kyrgidis A, Apalla Z, Ioannides D. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol. 2016;30(12): 2091-2096. https://doi.org/10.1111/jdv.13780
Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435-1444. https://doi.org/10.1111/j.1468-3083.2009.03372.x
Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C et al. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016; 2:CD009687. https://doi.org/10.1002/14651858.CD009687.pub2
Okubo Y, Natsume S, Usui K, Muro M, Tsuboi R. Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis. J Dermatol Treat. 2014;25(1):34-37. https://doi.org/10.3109/09546634.2012.687087
Ma L, Yang Q, Yang H, Wang G, Zheng M, Hao F, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2016;55(1): 106-113. https://doi.org/10.1111/ijd.12788
Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994; 130(4):483-487. https://doi.org/10.1111/j.1365-2133.1994.tb03382.x
Kragballe K, van de Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28(2):10-21. https://doi.org/10.1111/jdv.12444
Oostveen AM, de Jong EM, Donders AR, van de Kerkhof PC, Seyger MM. Treatment of pediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice. J Eur Acad Dermatol Venereol. 2015; 29(6):1193-1197. https://doi.org/10.1111/jdv.12789
Arnold WP. Tar. Clin Dermatol. 1997;15(5):739-744. https://doi.org/10.1016/s0738-081x(97)00018-7
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3: guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659. https://doi.org/10.1016/j.jaad.2008.12.032
Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0,05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatol Treat. 2006; 17(2):90-95. https://doi.org/10.1080/09546630500515701
Hillstrom L. Comparison of topical treatment with desoxymethasone solution 0,25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. J Int Med Res. 1984;12(3):170-173. https://doi.org/10.1177/030006058401200306
Hillstrom L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (diprosalic) and clobetasol propionate lotion (dermovate) in the treatment of psoriasis of the scalp. J Int Med Res. 1982;10(6):419-422. https://doi.org/10.1177/030006058201000606
Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res. 1983;11(2):108-112. https://doi.org/10.1177/030006058301100208
Kostarelos K, Teknetzis A, Lefaki I, Ioannides D, Minas A. Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. J Eur Acad Dermatol Venereol. 2000;14(1):5-9. https://doi.org/10.1046/j.1468-3083.2000.00006.x
Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol. 2004;17(2):91-97. https://doi.org/10.1159/000076019
Russian Society of Dermatovenerologists and Cosmetologists. Psoriasis. Federal clinical guidelines. M. 2023. (electronic document) (In Russ.). Accessed Sept 26, 2023.
Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, et al. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from arandomized, double-blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol. 2013;27(1):125-128. https://doi.org/10.1111/j.1468-3083.2011.04394.x
Menter A, Reich K, Li S, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol. 2008;58(2):AB120. https://doi.org/10.1016/j.jaad.2007.10.534
Thaci D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects onscalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015; 29(2):353-360. https://doi.org/10.1111/jdv.12553
Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab in the treatment of moderate-to-severe plaque psoriasis on the head and neck: pooled analysis of four phase 3 studies. Dermatology and Therapy. 2016;6(4):627-638. https://doi.org/10.1007/s13555-016-0139-0
Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015; 29(9):1763-1770. https://doi.org/10.1111/jdv.12996
Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016; 74(1):134-142. https://doi.org/10.1016/j.jaad.2015.09.001
Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiberoptic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol. 2004;43(6):462-467. https://doi.org/10.1111/j.1365-4632.2004.01993.x
Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2009; 23(1):36-41. https://doi.org/10.1111/j.1468-3083.2008.02942.x

Close metadata